Standard GHK-CU protocols use fixed doses (1-2mg) rather than weight-based calculations
It is important to note that GLP-1 receptor agonists are not currently licensed for the treatment of rheumatoid arthritis or other inflammatory conditions in the UK
CagriSema , the combination of cagrilintide and semaglutide, is another development showing promise, as detailed in the CagriSema dosing guide
Tirzepatide is typically initiated at 2.5 mg weekly and gradually increased at minimum 4-week intervals through 5 mg, 7.5 mg, 10 mg, 12.5 mg to a maximum of 15 mg based on individual response and tolerability
However, stopping the medication often leads to weight regaina pattern that highlights why weight loss medications work best as ongoing treatment rather than short-term fixes
Amalaki rasayan has very great results for the pacification of all three doshas